IDH1 and glioblastoma: A different approach using LITT as a disrupter of the blood brain barrier (BBB) (22) combined with ICI for the treatment of recurrent IDH-wild-type glioblastoma in adult patients is being explored in a prospective randomized controlled trial (NCT02311582).